Department of Microbiology, Punjab Agricultural University, Ludhiana, India.
Trafford College, Altrincham, Manchester, UK.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2068883. doi: 10.1080/21645515.2022.2068883. Epub 2022 May 4.
Since commencement of COVID-19 pandemic, several SARS-CoV-2 variants have emerged amid containment efforts vaccination. The Delta variant (B.1.617.2), discovered in October 2020, was designated as a VOC by the WHO on May 11, 2021. The enhanced transmissibility of Delta variant has been associated with critical mutations such as D614G, L452R, P681R, and T478K in the S-protein. The increased affinity of the S-protein and ACE2 has been postulated as a key reason for decreased vaccine efficacy. As per evidence, the Delta variant possesses increased transmissibility and decreased vaccine efficacy compared to other VOCs like Alpha and Beta. This has led to concerns regarding the acquisition of novel mutations in the Delta variant and outbreaks in vulnerable communities, including vaccinated people. In this mini-review of Delta variant, we have explained its evolution and characteristics, the impact of spike mutations on infectivity and immune evasion, and measures to combat future outbreaks.
自 COVID-19 大流行开始以来,在遏制努力和疫苗接种过程中出现了几种 SARS-CoV-2 变体。Delta 变体(B.1.617.2)于 2020 年 10 月发现,于 2021 年 5 月 11 日被世界卫生组织指定为 VOC。Delta 变体的增强传染性与 S 蛋白中的关键突变有关,例如 D614G、L452R、P681R 和 T478K。假定 S 蛋白和 ACE2 的亲和力增加是疫苗效力降低的一个关键原因。有证据表明,与其他 VOC(如 Alpha 和 Beta)相比,Delta 变体具有更高的传染性和更低的疫苗效力。这引起了人们对 Delta 变体中新出现的突变和易受感染人群(包括接种疫苗的人群)爆发的担忧。在对 Delta 变体的简要回顾中,我们解释了它的进化和特征、刺突突变对感染性和免疫逃避的影响,以及应对未来爆发的措施。